Media

Safer Psychedelic Drugs May Be Coming

MDMA Drug Developers Reprioritize Following Lykos Rejection in PTSD

How the next psychedelics companies believe they can avoid Lykos’ fate

Atai’s DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant

Atai advances oral psychedelic in depression

Atai Touts Early Data on Psychedelic Depression Drug, Plans Phase II Trial

Our team share their thoughts about the unmet need in mental health, the science behind our programs and more.

Thought leadership